-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Neutral on LAVA Therapeutics, Maintains $1.5 Price Target

Benzinga·03/31/2025 10:48:09
Listen to the news
HC Wainwright & Co. analyst Arthur He reiterates LAVA Therapeutics (NASDAQ:LVTX) with a Neutral and maintains $1.5 price target.